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OBJECTIVES: Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab
lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for
quantitative determination of infliximab and to assess thresholds associated with mucosal healing in patients with ulcerative
colitis.
METHODS: Samples (n= 190) from 29 anti-tumor necrosis factor naive patients with ulcerative colitis starting infliximab induction
therapy between June 2010 and February 2012 were prospectively collected. All patients had a Mayo endoscopic sub-score ≥ 2 at
baseline. Mucosal healing (MH), defined as a Mayo endoscopic sub-score ≤ 1, was evaluated at week 10–14. Infliximab trough
concentrations (TC) were determined with a novel LFA, which was benchmarked with the RIDASCREEN infliximab Monitoring
(ELISA).
RESULTS: The LFA showed an excellent agreement with enzyme-linked immunosorbent assay (ELISA) for quantification of
infliximab, as observed from Pearson and intraclass correlation coefficients of 0.95 and 0.95 during induction and 0.93 and 0.87
during maintenance therapy, respectively. In total, 45% of patients achieved MH. Using the LFA, week 14 TC ≥ 2.1 μg/ml (AUROC:
0.819, P= 0.008) were associated with MH. After 2 years follow-up, 77% of patients with MH were still receiving infliximab therapy
vs. 25% of patients without MH.
CONCLUSIONS: We validated a LFA for quantification of infliximab and identified TC associated with MH. With a time-to-result of
20 min, individual sample analysis and user-friendliness, the LFA outplays ELISA as a rapid, accurate tool to monitor infliximab
concentrations.
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INTRODUCTION
Therapeutic drug monitoring of infliximab has become
increasingly important in optimizing therapy of patients with
inflammatory bowel diseases. The trough concentration (TC)
of infliximab, which is the drug concentration in serum just
before the next infusion, has been linked to biological, clinical,
and endoscopic outcomes.1–3 Recently, several prospective
trials have identified concentration-based dosing as a cost-
effective alternative to clinically based dosing.4,5 However,
dosing could only be adapted at the next infusion of infliximab,
typically 8 weeks later, because of the lack of a rapid
infliximab assay.
The conventional assays used for therapeutic drug monitor-
ing of infliximab are enzyme-linked immunosorbent assays
(ELISA), radio-immunoassays, or homogeneous mobility shift
assays.6–9 Several comparison studies have been performed
and although all assays were shown to correlate very well,
small differences in measured infliximab concentration
between assays were observed.10–14 However, these differ-
ences are supposed to have limited effect on clinical outcome,
as demonstrated by Steenholdt et al.15 Infliximab assays are
usually performed in a hospital laboratory, are time-consuming
and require analysis of multiple samples at a time to reduce
costs. Consequently, these assays do not allow immediate
dose optimization and hamper the implementation of
therapeutic drug monitoring in a hospital or infusion setting.
In this study, we present a novel lateral flow-based assay
(LFA) for rapid infliximab quantification. The LFA was
benchmarked to a reference infliximab ELISA using 190
serum samples, prospectively collected from a cohort of 29
patients with ulcerative colitis starting infliximab. In
addition, we determined infliximab concentration thresholds
associated with mucosal healing (MH) following induction
treatment.
METHODS
Study design, definitions, and patient population. In this
prospective observational study, we included anti-tumor
necrosis factor naive patients diagnosed with moderate–
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severe ulcerative colitis that started infliximab treatment.16
Only patients with active disease, as confirmed by an
endoscopic evaluation at baseline, and with an endoscopic
evaluation after scheduled infliximab induction therapy
(w10–14) were included. Active disease was defined as a
Mayo endoscopic sub-score of 2 or 3. MH was defined as a
Mayo endoscopic sub-score of 0 or 1 after infliximab
induction therapy. Serum samples were prospectively
collected during infliximab induction (w0, 2, and 6) and
maintenance therapy (w14 onward for up to 2 years), just
before an infliximab infusion, centrifuged and stored at −
20 °C. Long-term infliximab survival was defined as continua-
tion of infliximab therapy for over 2 years. Written informed
consent was provided by all patients in the framework of the
Institutional Review Board-approved Flemish Inheritance
study for Crohn’s and colitis (VLECC; B322201213950/
S53684).
Infliximab concentrations. Infliximab concentrations in
serum samples (including but not limited to w0, w2, w6,
w14, w30, and w54 samples) were determined using a novel
LFA (R-Biopharm AG, Darmstadt, Germany) and the
RIDASCREEN infliximab Monitoring (ELISA) (R-Biopharm
AG)—both using the specific monoclonal anti-infliximab
antibody mAb-IFX6B7.8
In the LFA, serum samples were measured according to the
manufacturer’s instructions, consisting of a 5 min pre-
incubation of diluted sample with “Solution A” and “Solution
B” and 15 min developing time on the lateral flow strip.
Subsequently, the lateral flow strips were read using a
portable LFA reader. The LFA revealed a dose-response
curve in the 0.5–40 ng/ml range (r2= 0.9995), which was fitted
using four parameter logistic regression (y ¼ d þ ad
1þ x=cð Þb,
Supplementary Figure S1). The dose-response curve was
validated in the 1–20 ng/ml range. For the determination of
serum samples withdrawn during the induction phase of
infliximab (w2 and 6), a 1:2000 dilution was applied. For anti-
tumor necrosis factor naive samples and samples withdrawn
during the maintenance phase (including but not limited to w0,
w14, w30, and w54), a 1:500 dilution was applied.
The RIDASCREEN infliximab Monitoring (ELISA) was
carried out according to the manufacturer’s instructions and
has a lower limit of quantification of 0.5 μg/ml infliximab. For
the determination of serum samples, a 1:400 dilution was
applied. All other serum samples were determined as
described before using an in-house developed and clinically
validated infliximab ELISAwith a lower limit of quantification of
0.5 μg/ml.8
Anti-infliximab antibodies. Anti-infliximab antibodies (ATI)
were measured using a drug-sensitive and novel
drug-tolerant ELISA as described in the Supplementary Data
section.17
Statistical analysis. All statistics were carried out using the
statistical programs Graphpad Prism 5.0 (Graphpad
software, San Diego, CA, USA) and IBM SPSS Statistics
23 (IBM SPSS, Costa Mesa, CA, USA). Data are expressed
as median and interquartile range for continuous variables
and frequency and percentage for categorical variables
unless stated otherwise. Normality was assessed using the
D′Agostino–Pearson test. For the univariate analysis of
unpaired continuous variables, either an unpaired t-test
or independent 2-group Mann–Whitney U-test was used.
Univariate analysis of discrete variables was performed using
the Fisher’s exact test. Correlations and agreements between
LFA and ELISA were assessed using the Pearson r
correlation coefficient and the intraclass correlation
coefficient (ICC; two-way mixed, absolute agreement—single
measures). The ICC allows to reveal systematic differences
between two methods that would go unnoticed using a
Pearson r. The proportion of positive and negative agreement
between LFA and ELISA was determined by the average
number of patient samples identified as positive and negative
by either method, respectively, assuming none of the two
methods is the golden standard. Infliximab concentrations
exceeding the lower and upper assay quantification limits
were not taken into account for statistical analysis. Receiver
operating characteristic (ROC) analysis was performed to
assess infliximab concentration thresholds associated with
MH. Optimal thresholds were selected using the Youden’s
Table 1 Baseline characteristics of patients with ulcerative colitis
All patients MH No MH P-value
n (%) 29 (100) 13 (45) 16 (55)
Gender (male/female) 19/10 7/6 12/4 0.3
BMI, kg/m2, mean± s.d. 25.6±4.1 26.4±4.6 25.0±3.6 0.5
UC extension: E3 (pancolitis), n (%)a 11 (44) 4 (31) 7 (44) 0.4
Mayo endoscopic sub-score before IFX, Mayo 3 (%) 12 (41) 4 (31) 8 (50) 0.5
Acute severe colitis, n 2 1 1 1.0
Age at first IFX, y, median (IQR) 43 (28–51) 29 (24–53) 45 (31–51) 0.4
Duration of disease at first IFX, y, median (IQR) 3.0 (1.4–8.4) 3.4 (1.9–8.0) 2.3 (1.3–9.4) 0.5
CRP concentration, mg/l, median (IQR) 3.7 (2.1–13.4) 3.7 (1.5–14.2) 3.5 (2.2–12.0) 0.8
Albumin, g/l, median (IQR) 42.5 (39.7–45.4) 42.1 (40.7–44.9) 43.2 (38.4–45.9) 0.9
Current smokers, n 4 3 1 0.3
Immunomodulator use, n (%) 12 (41) 8 (62) 4 (25) 0.07
Corticosteroid use, n (%) 9 (31) 3 (23) 6 (38) 0.5
BMI, body mass index; CRP, C-reactive protein; IFX, infliximab; IQR, interquartile range; MH, mucosal healing; UC, ulcerative colitis.
aAccording to Montreal classification.
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index to maximize the sum of specificity and sensitivity. A log-
rank test was performed to assess differences in long-term
infliximab survival.
RESULTS
Study population. Twenty-nine patients met the study
inclusion criteria and were included in this post hoc analysis.
Demographic characteristics of these patients are provided in
Table 1. All but two patients received the standard 5 mg/kg
induction treatment on week 2, 6, and 14. The two other
patients received an intensified dosing regimen. In total,
13/29 (45%) patients achieved MH. Seven out of 29 (24%)
patients discontinued infliximab treatment after induction, of
which six patients because of lack of response (no MH) and
one because of dermatological side reactions (Figure 1). A
significant difference in long-term infliximab survival was
observed between patients with and without MH (P=0.004,
log-rank test).
Infliximab concentrations. In total, 190 unique patient
samples were analyzed in parallel by the LFA and
ELISA (Table 2). A very good correlation and ICC was
observed for samples withdrawn during induction (Figure 2a,
Pearson r of 0.95 and ICC of 0.95, n=41) and maintenance
of infliximab treatment (Figure 2b, Pearson r of 0.93 and ICC
of 0.87, n= 84). In addition, a good agreement was observed
in the Bland–Altman plots, showing an average bias of
0.5 (95% confidence interval: −5.5 to 6.6) μg/ml infliximab
for induction treatment samples (Figure 3a) and −0.8
(95% confidence interval: −2.7 to 1.1) μg/ml for
maintenance treatment samples (Figure 3b) between the
LFA and ELISA.
Out of 28 available anti-tumor necrosis factor naive samples
(w0), only one sample revealed a slightly elevated infliximab
concentration of 0.51 μg/ml, which is just above the quantifica-
tion limit of the assay (0.50 μg/ml). The positive and negative
percent agreement between LFA and the reference ELISA are
Figure 1 Short- and long- term response of 29 patients with ulcerative colitis treated with infliximab.
Table 2 Intention-to-diagnose analysis of patient samples
Sampling date w0 w2 w6 w14 w30 w54 Other Total
Intention-to-
diagnose
29 29 29 24 19 18 44 192
Measured samples 28 29 28 24 19 18 44 190
Missing samples 1 0 1 0 0 0 0 2
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99.7% and 98.6%, respectively. In addition, 10 samples were
re-tested using LFA and ELISA demonstrating excellent
reproducibility with an average coefficient of variation of
8± 6% and 5± 2%, respectively.
Association of infliximab trough concentrations and
mucosal healing. Infliximab concentrations were higher in
patients with MH than in patients without MH (Figure 4),
but the difference was only significant at week 14
(P=0.007). Receiver operating characteristic analysis
identified an infliximab concentration threshold ≥ 2.1 μg/ml
at week 14 using the LFA (Figure 5, area under the ROC
curve (AUROC) of 0.819, P= 0.008, sensitivity 100%,
specificity 50%) and ≥ 2.7 μg/ml using ELISA (AUROC of
0.802, P=0.012, sensitivity 100%, specificity 50%) to be
associated with MH. This cut-off implies that 50% of patients
without MH have infliximab concentrations lower than 2.1 μg/
ml. Our results, however, indicate that these patients benefit
from an intensified dosing regimen as three out of four
patients with a TCo2.1 μg/ml at w14 who started
infliximab maintenance therapy and received intensified
therapy, successfully completed 2 years of infliximab
treatment. In addition, the positive and negative percent
agreement of the LFA with ELISA at the ELISA
Figure 2 Correlation analysis of week 2 and 6 serum samples (a, n= 41) and maintenance treatment serum samples (b, n= 84).
Figure 3 Bland–Altman plots of week 2 and 6 serum samples (a, n= 41) and maintenance treatment serum samples (b, n= 84), including the average bias (solid line) and
95% limits of agreement (dotted line) between lateral flow-based assay (LFA) and enzyme-linked immunosorbent assay (ELISA).
Figure 4 Infliximab concentrations at w2, w6, and w14 in patients with and without mucosal healing.
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cut-off of 2.7 μg/ml was determined to be 94% and 100%,
respectively.
Anti-infliximab antibodies. In total, 221 serum samples
were tested using the drug-sensitive and novel drug-tolerant
assay. During the 1 year follow-up, the drug-sensitive
anti-infliximab assay detected ATI in 4/29 patients (14%),
whereas the drug-tolerant anti-infliximab assay identified
10/29 patients (34%) with ATI on at least one time point
(Supplementary Figure S2). In total, 5/221 (2%) samples
and 35/221 (16%) samples were ATI positive using the
drug-sensitive and drug-tolerant assay, respectively. All four
patients with positive ATI in the drug-sensitive bridging ELISA
had at that time no detectable TC and were also identified as
ATI positive using the drug-tolerant assay.
Two out of eight patients who failed infliximab maintenance
treatment suffered from an infusion reaction and delayed
hypersensitivity associated with high ATI, which
were detected 48 and 33 weeks before the adverse event
using the drug-tolerant assay and 40 and 17 weeks
using the drug-sensitive assay, respectively (Supplementary
Figure S3). The six other patients stopped because of
insufficient response to therapy despite quantifiable TC—only
one of these patients had detectable ATI using the
drug-tolerant approach at the time of infliximab
discontinuation.
DISCUSSION
The advent of biological therapies, such as infliximab,
revolutionized the treatment of patients with refractory
inflammatory bowel diseases, but raised as well-significant
pharmaco-economic concerns. Although hospitalizations and
surgical interventions decreased, cost of drug strongly
increased. The main challenging goal for the future is to use
biologicals as effective as possible. Therapeutic drug monitor-
ing has, therefore, been introduced to guide the treatment of
patients with inflammatory bowel disease and improve clinical
outcomes.
Sufficient evidence in favor of therapeutic drug monitoring
during maintenance infliximab therapy has been demon-
strated in a number of clinical trials linking TC with clinical
outcome.1,2,18 In a post hoc analysis of the SONIC trial,
TC43.0 μg/ml at week 30 were significantly associated with
MH at week 26.19 In a meta-analysis of Moore et al.,20
TC42.0 μg/ml were associated with a greater probability of
clinical remission and MH. A study of Arias et al.21 identified a
w14 TC42.5 μg/ml to be associated with relapse-free
infliximab survival and colectomy-free survival. In addition,
prospective trials such as the TAXIT trial demonstrated that a
TC target window of 3–7 μg/ml increases the number of
patients in clinical remission at a lower cost.4
Recently, the scope of therapeutic drugmonitoring has been
widened to the induction phase of infliximab therapy.22–25
A Dutch group reported an infliximab serum concentration of
6.6 μg/ml at week 6 as a cut-off value for endoscopic response
in patients with moderate–severe UC.24 Another study
identified infliximab concentration thresholds of 28.3, 15.0,
and 2.1 μg/ml at week 2, 6, and 14, respectively, to be
associated with short-term MH in UC patients.25 It is
hypothesized that in some patients, infliximab is cleared more
rapidly due to a high baseline disease burden, early
anti-infliximab antibody formation, or other pharmaco-kinetic
and -dynamic mechanisms leading to an underexposure of
patients to infliximab and subsequently insufficient clinical
response. These patients may benefit from an intensified
infliximab dosing regimen. However, the current available
assays to perform drug monitoring only allow a dose
optimization at the next patient’s hospital visit, limiting their
use.6–9 The feasibility of a rapid assay for infliximabmonitoring
has previously been demonstrated in two studies using
either a LFA or a fiber optic-surface plasmon resonance
technology.26,27 However, both assays still require multiple
manipulations, extensive validation and are not available for
routine use.
Here, we present a novel, rapid LFA for infliximab
quantification that is accurate, accessible, and affordable.
The LFA is accurate. A blindly performed, parallel analysis of
190 serum samples of patients with ulcerative colitis using the
LFA and a reference ELISA revealed an excellent correlation
for induction and maintenance treatment samples.
Re-analysis of 10 patient samples on an independent time
point revealed a high reproducibility of the LFA. The analysis of
28 anti-tumor necrosis factor naive samples on LFA revealed
one false-positive quantification of infliximab (0.51 μg/ml),
which was only marginally higher than the assay cut-off
(0.50 μg/ml). This value is considered not to alter clinical
decisions. The LFA is accessible. The bench top-sized reader
(Supplementary Figure S4) can be placed in any hospital/
infusion center and the comprehensive assay format does not
require extensive laboratory skills. With a time-to-result of
roughly 20 min clinicians have immediate access to the results
and may adapt the infliximab dosing regimen within a patient’s
Figure 5 Receiver operating characteristic analysis of week 14 infliximab trough
concentrations, measured with the lateral flow-based assay, showing an AUROC of
0.819 (P= 0.008, 95% confidence interval: 0.652–0.987). An infliximab concentration
threshold of 2.1 μg/ml was found to be associated with mucosal healing.
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hospital visit. One drawback of the current assay format is that
it still requires a blood collection and serum preparation, but
this allows adequate comparison of the LFA with the current
available standard methods and application of the established
therapeutic drug monitoring-based treatment algorithms. In
addition, the LFA is CE-marked and is currently only available
in Europe. There is no need to collect a series of samples
before an analysis can be performed as a single sample can
be measured. Moreover, it avoids the need of costly sample
transportation to a centralized, fully equipped, laboratory.
The final pricing will depend on distributor, country, laboratory,
and end user.
In our study, using the LFA, a TC≥2.1 μg/ml
infliximab at week 14 was identified as a cut-off associated
with MH, which is equal to the cut-off determined in a larger
cohort of 101 patients (of which 20/101 patients overlap in this
study cohort).25 In contrast to the study of Papamichael
et al.,25 we could not identify cut-offs at week 2 and week 6
associated with MH, probably related to the small sample size
used. The cut-off of 2.1 μg/ml infliximab has a sensitivity of
100%, but a specificity of only 50%, indicating that 50% of
patients without MH have infliximab concentrations o2.1 μg/
ml at week 14. Our results, however, indicate that these
patients may benefit from an intensified dosing regimen as
three out of four patients with a TCo2.1 μg/ml at w14 who
started infliximab maintenance therapy and received
intensified therapy, successfully completed 2 years of
infliximab treatment. These results are to be confirmed in a
larger prospective trial.
In addition, we determined the evolution of ATI over time
using a drug-sensitive and novel drug-tolerant ELISA; the latter
assay was expected to increase the number of ATI-positive
samples. We could strengthen this as four patients (14%) or
5/221 samples (2%) were ATI positive using the drug-sensitive
assay vs. 10 patients (34%) or 35/221 samples (16%)
with the drug-tolerant assay. Two patients had to stop
infliximab maintenance treatment because of an adverse event
associated with high ATI titers. These ATI were already
detected 48 and 33 weeks before the adverse event
using the drug-tolerant assay. It is hypothesized that these
patients could have had benefit from an early treatment
optimization.
This study has some limitations. As the amount of
lateral flow strips available was restricted, we opted to apply
these strips in a well-defined cohort of only 29 patients to
validate the LFA performance. Hence, the modest
sample size used may limit our associations of TCs
with MH. In addition, because a post hoc analysis was
performed, not all factors that could explain the variability in
response, such as fecal calprotectin levels, were included in
this study.
In conclusion, we validated a novel LFA which is sensitive,
selective, and highly specific for infliximab. Using the LFA we
identified an infliximab threshold ≥2.1 μg/ml at week 14 to be
associated with MH in patients with ulcerative colitis. With a
time-to-result of 20 min, individual sample analysis and user-
friendliness, the LFA outplays ELISA as a rapid, accurate tool
to monitor infliximab concentrations facilitating clinical
decision-making. The novel drug-tolerant ATI assay improves
the detection of ATI and allows an early identification of
patients at risk for developing excessive ATI and associated
treatment failure.
CONFLICT OF INTEREST
Guarantor of the article: Ann Gils, PharmD, PhD.
Specific author contributions: TVS helped with the
design of the study, performed research, interpreted data,
implemented statistical analyses, and drafted the
manuscript. LB and KP helped with the acquisition of data and
critically revised the manuscript. NVC critically revised the
manuscript. GVA and MF provided patient samples and
critically revised the manuscript. SV provided patient samples,
helped with the acquisition and interpretation of data, and
critically revised the manuscript. AG designed the study,
coordinated the experiments, interpreted data, and
critically revised the manuscript for intellectual content.
All the authors read and approved the final version of the
manuscript.
Financial support: This study was financially supported in
part by C2 grant C22/15/025 from the KU Leuven.
TVS is a PhD fellow of the Agency for the Promotion and
Innovation through Science and Technology in Flanders
(IWT, Flanders). NVC is a Postdoctoral Fellow of the Research
Foundation—Flanders (FWO), Belgium; grant number
1260714N and received speakers fees from AbbVie and
consultancy fees from MSD, Janssen Biologics, Pfizer, UCB,
and Takeda. KP received a Fellowship Grant from the
Hellenic Society of Gastroenterology. GVA received financial
support for research from Abbott and Ferring
Pharmaceuticals, lecture fees from Janssen,
MSD and Abbott, and consultancy fees from
PDL BioPharma, UCB Pharma, Sanofi-Aventis, Abbott,
Abbvie, Ferring, Novartis, Biogen Idec, Janssen Biologics,
NovoNordisk, Zealand Pharma A/S, Millenium/Takeda, Shire,
Novartis, and Bristol Mayer Squibb. MF received financial
support for research from Takeda, lecture fees from MSD,
Janssen, Abbvie, Boehringer-Ingelheim, Ferring, Chiesi,
Tillotts, Zeria, and Mitsubishi Tanabe, and consultancy fees
from MSD, Janssen, Abbvie, Boehringer-Ingelheim, and
Ferring. SV received grant support from MSD, Abbvie and
Takeda, lecture fees from Abbvie, MSD, Ferring
Pharmaceuticals, Takeda, Hospira and consultancy fees from
Abbvie, Takeda, Pfizer, Ferring Pharmaceuticals, Shire
Pharmaceuticals Group, MSD, Hospira, Mundipharma,
Celgene, Galapagos, Genentech/Roche. AG has served as a
speaker for MSD, Janssen Biologicals, Pfizer, Takeda and
Abbvie, as consultant for UCB and has received Investigator
Initiated Research Grants from Pfizer. KU Leuven licensed the
infliximab ELISA to apDia and R-Biopharm and the use of
monoclonal antibody—mAb-IFX6B7—in the LFA to
R-Biopharm.
Potential competing interests: None.
Acknowledgments. We would like to thank R-Biopharm AG for providing us
with the lateral flow cassettes, the reagentia, and the portable reader. We
acknowledge the valuable expertise of Chris Barthel, Yessica Kölmel, Nasim Zali, and
Steffen Rameil.
Rapid Inﬂiximab Quantiﬁcation
Van Stappen et al.
6
Clinical and Translational Gastroenterology
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Trough concentrations during induction and maintenance
therapy are associated with clinical response.
✓ Therapeutic drug monitoring of infliximab improves
outcomes in patients with inflammatory bowel disease.
✓ The current available drug monitoring assays do not allow
immediate dose adaptations.
WHAT IS NEW HERE
✓ A lateral flow assay for infliximab quantification has a turn-
around time of only 20 min.
✓ The lateral flow assay shows excellent agreement with a
clinically validated enzyme-linked immunosorbent assay
(ELISA).
✓ A trough infliximab concentration ≥ 2.1 μg/ml at week 14 is
associated with mucosal healing.
✓ The rapid infliximab assay will allow immediate treatment
optimization based on drug exposure.
✓ The rapid infliximab assay will facilitate implementation of
therapeutic drug monitoring in hospitals/infusion centers.
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